Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst
Pfizer Inc shares slipped roughly 1.1% to $26.49 in premarket action Friday, following Thursday’s close near $26.79.
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill
Shares of Hims & Hers Health dropped 3.8% to $23.48 in premarket trading on Friday. The slide came after FDA Commissioner Marty Makary warned the agency would act quickly against firms mass-marketing “illegal copycat drugs.” The stock had already fallen 3.8% on Thursday and plunged nearly 10% after hours, following Makary’s post on X stating, “The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs.” His comments came after Hims introduced a compounded version of Novo Nordisk’s Wegovy weight-loss medication.
Hims & Hers stock slips premarket after FDA “illegal copycat drugs” warning clouds $49 Wegovy-style pill
Shares of Hims & Hers Health dipped 3.8% to $23.48 in premarket trading Friday, following a tough day on Thursday.
Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats
Novo Nordisk A/S shares climbed 4.7% in early trading on Friday after the U.S. Food and Drug Administration pledged to crack down on mass-marketing of unapproved drug copies. By 0848 GMT, the stock was up 4.9% at 294.50 Danish crowns.
Pfizer stock faces a Friday test after TrumpRx discounts hit the tape
Pfizer shares slipped 1.1% to close at $26.49 on Thursday, ahead of the company’s launch of fresh discounts linked to the TrumpRx platform. During the day, the stock fluctuated between $26.46 and $27.19.
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss
AbbVie Inc shares climbed roughly 0.7% to $219.02 in after-hours trading Thursday, following an intraday range between $214.27 and $221.00.
Hims & Hers (HIMS) stock whipsaws on $49 Wegovy copycat pill as legal, FDA risks sharpen
Hims & Hers Health shares ended Thursday at $23.48, slipping 3.8% after volatile trading tied to its shift toward a cheaper, compounded form of Novo Nordisk’s new Wegovy pill.
Johnson & Johnson stock price holds near $238 after-hours as Supreme Court talc case move hits
Johnson & Johnson shares jumped about 1.4% Thursday, then held steady after hours. The move came as the company asked the U.S. Supreme Court to weigh in on whether a shareholder lawsuit accusing it of misleading statements about talc safety can move forward as a class action. The petition seeks clarification on the court’s 2021 Goldman Sachs ruling, focusing on how “price impact” — whether alleged falsehoods affected stock prices — factors into certifying investor groups. JNJ last changed hands at $237.79, after trading between $233.33 and $240.00 during regular hours.
Eli Lilly stock price sinks after $49 weight-loss pill jolt hits LLY
Eli Lilly shares dropped 7.8% to $1,020.84 in after-hours trading Thursday, reversing course sharply after swinging between $1,113 and $1,006 during the day.
Hims & Hers stock whipsaws on $49 Wegovy-copy pill as legal threats cloud next move
Shares of Hims & Hers Health dropped 3.2% to $23.63 Thursday afternoon, as the telehealth company expanded into the weight-loss drug market by launching a $49 compounded version of Novo Nordisk’s new Wegovy pill. The stock fluctuated between $22.98 and $29.44 on heavy volume.
Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval
Shares of Merck & Co., Inc. climbed roughly 2% Thursday afternoon, hitting $120.72. The stock swung between $117.34 and $122.39, with volume near 12.8 million shares.
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court
Johnson & Johnson shares climbed 1.3% to $237.59 in afternoon trading, pushing their recent gains further. The move came after the company petitioned the U.S. Supreme Court to review a shareholder lawsuit concerning claims about the safety of its talc products.
Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view
Bristol Myers Squibb shares climbed 1.7% to $58.58 by midday Thursday, having peaked earlier at $60.54. This came as the S&P 500 slipped around 0.7%, with health-care stocks also drifting lower.
Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook
Pfizer shares climbed 0.8% to $27.01 by 12:43 p.m. EST, building on a rebound after a volatile stretch triggered by fresh trial data and a quarterly earnings report.
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action
Shares of Hims & Hers Health Inc swung sharply Thursday following the company’s announcement that it plans to offer a low-cost compounded version of Novo Nordisk’s new Wegovy weight-loss pill. Novo Nordisk promptly threatened legal action. The stock bounced back to $24.41 in late morning trading after earlier surging to $29.44.
Eli Lilly stock slides after $49 Wegovy copy stirs fresh price-war jitters in obesity drugs
Eli Lilly and Company shares dropped 6.2% to $1,038.52 in Thursday's morning session, after fluctuating between $1,113 and $1,029 earlier.
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop
Pfizer Inc shares gained 3.9%, closing at $26.78 on Wednesday, then held steady in after-hours trading. The move capped a volatile two days driven by fresh obesity drug data and quarterly earnings.
Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines
Merck & Co shares climbed roughly 2.2% in after-hours trading Wednesday, closing at $118.33, after hitting a peak of $120.36 during the session.
AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view
AbbVie shares dropped in after-hours trading Wednesday following the release of its fourth-quarter results and a 2026 profit forecast. Investors focused on weaker-than-anticipated sales for the newer immunology drug Rinvoq. The stock last traded down 3.9% at $217.11, hitting a low of $204.98 earlier in the session.
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates
AbbVie Inc shares fell 2.5% to $219.98 in afternoon trading Wednesday, hitting a low of $204.98 earlier in the session.